TITLE

Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease

AUTHOR(S)
Perez-Lloret, Santiago; Rascol, Olivier
PUB. DATE
November 2010
SOURCE
CNS Drugs;2010, Vol. 24 Issue 11, p941
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate or advanced Parkinson's disease as well as for the reduction of levodopa-related motor complications. Ergolinic dopamine agonists, such as bromocriptine or pergolide, were initially developed and marketed, and then non-ergolinic dopamine agonists, such as pramipexole and ropinirole, were introduced, reducing the risk of drug-induced fibrotic reactions. Once-daily, controlled-release oral and transdermal formulations have been developed aiming at providing more stable 24-hour plasma drug concentrations and more convenient administration. A disease-modifying effect of dopamine agonists has not been demonstrated clinically. As with any other drug, dopamine agonists can also cause adverse drug reactions, which can be related or unrelated to dopaminergic hyperactivation. Dopaminergic reactions include nausea, hallucinations, confusion and ortho- static hypotension, among others, which were readily identified in pre-marketing clinical trials. During post-marketing surveillance, important adverse reactions were identified, such as daytime somnolence, impulse-control disorders and heart valve fibrosis. Other issues, including the efficacy of dopamine agonists for the treatment of non-motor symptoms, remain under evaluation.
ACCESSION #
56104704

 

Related Articles

  • Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease : A short commentary. Quinn, N. P. // Journal of Neurology;Jan2003, Vol. 250 Issue 1, p97 

    Comments on ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. Effect of dopamine agonists on Parkinson's disease patients on chronic levodopa therapy; Equivalence between adjunctive ropinirole and bromocriptine.

  • Potential of Transdermal Drug Delivery in Parkinson's Disease. Pfeiffer, R.F. // Drugs & Aging;2002, Vol. 19 Issue 8, p561 

    There has been a growing recognition that pulsatile stimulation of dopamine receptors may be an important mechanism in the generation of the motor fluctuations that often develop and compromise the effectiveness of long-term levodopa administration in persons with Parkinson's disease (PD). This...

  • Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease : A 16-week bromocriptine controlled study. Joo-Hyuk Im; Jeong-Ho Ha; In-Sook Cho; Myoung C. Lee // Journal of Neurology;Jan2003, Vol. 250 Issue 1, p90 

    Background: and objectives Ropinirole is a non-ergoline, selective dopamine D2 agonist. The aim of this study was to evaluate the efficacy and safety of ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease (PD) complicated by motor fluctuations. Methods: A total of 76...

  • Continuous dopaminergic stimulation and novel formulations of dopamine agonists. Stocchi, Fabrizio // Journal of Neurology;May2011, Vol. 258 Issue 2, p316 

    There is now accumulating evidence that the combination of progressive pathology of Parkinson's disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors are the key contributing factors to the priming...

  • Bromocriptine. Vance, Mary Lee; Evans, William S.; Thorner, Michael O. // Annals of Internal Medicine;Jan84, Vol. 100 Issue 1, p78 

    Focuses on the use of dopamine receptor bromocriptine in the treatment of various hyperprolactinemic conditions and as adjuctive therapy for acromegaly and Parkinson's disease. Suppression of prolactin secretion; Restoration of gonadal function and fertility; Decrease in size of...

  • bromocriptine.  // Royal Society of Medicine: Medicines;2002, p121 

    The article presents information on bromocriptine, an ergot alkaloid used to treat parkinsonism. It works by stimulating the dopamine receptors in the brain and so is different to the more commonly used treatment with levodopa, which is converted to dopamine in the body. It is therefore...

  • Rotigotine Transdermal Patch. Sanford, Mark; Scott, Lesley J. // CNS Drugs;2011, Vol. 25 Issue 8, p699 

    A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro®) is indicated as monotherapy for the treatment of early Parkinson's disease and as combination therapy with levodopa throughout the course of the disease. Daily application of the rotigotine transdermal...

  • Which drugs work best for early Parkinson's disease? Jam, Liza; Benko, Rebecca; Safranek, Sarah // Journal of Family Practice;Feb2012, Vol. 61 Issue 2, p106 

    The article discusses two medications in treating early Parkinson's disease. It mentions the use of Levodopa/carbidopa as medication for Parkinson's disease, but may result on the occurrence of dyskinesia and dystonia. It also cites the use of bromocriptine, a dopamine agonist for treating...

  • Company filing NDA for new Parkinson's drug. Rogers, Katie // Drug Topics;2/19/96, Vol. 140 Issue 4, p54 

    Focuses on pramipexole, a novel dopamine agonist codeveloped by Boehringer Ingelheim and Pharmacia & Upjohn. Potential drug for the treatment of Parkinson's disease; De novo therapy in early Parkinson's disease.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics